# Empagliflozin + Linagliptin

## Glyxambi 25/5mg

##### 

| TAH Drug Code      | OGXB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Type 2 diabetes mellitus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dosing             | Initial empagliflozin 10 mg/linagliptin 5 mg orally once daily in the morning, may increase to empagliflozin 25 mg/linagliptin 5 mg once daily if tolerated.                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | Severe renal impairment, dialysis, or end-stage renal disease. Hypersensitivity reaction to empagliflozin, linagliptin, or any of the excipients; anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred.                                                                                                                                                                                                                                                                                                                                       |
| Adverse Effects    | Common Renal: Urinary tract infectious disease (11.4% to 12.5% ) Respiratory: Nasopharyngitis (5.9% to 6.6% ), Upper respiratory infection (7% ) Serious Cardiovascular: Heart failure, Hypotension Endocrine metabolic: Diabetic ketoacidosis, Hypoglycemia (2.2% to 3.6% ) Gastrointestinal: Pancreatitis Immunologic: Hypersensitivity reaction Musculoskeletal: Arthralgia Renal: Creatinine clearance-glomerular filtration abnormal, Decreased, Pyelonephritis, Sepsis due to urinary tract infection, Serum creatinine raised Reproductive: Necrotizing fasciitis, Perineum Other: Angioedema |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

